Skip to main content

Table 1 Patients’ characteristics

From: Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate

Patient

Sex

Age (years)

Weight (kg)

Primary tumor

Metastases

Injected activity (MBq)

Number of treatment cycles

SPECT/CT acquisition times

C1

C2

C1

C2

1

M

75

74

Small intestine NET

Nodes, mesentery, liver

7167

7073

4

NA

4 h, 24 h, 72 h, 192 h

2

M

59

72

Small intestine NET

Nodes, liver, bone

7287

1

4 h, 24 h, 168 h

3

M

82

70

Small intestine NET

Nodes, mesentery, bone

7180

6642

2

4 h, 24 h, 72 h

4 h, 24 h, 72 h, 192 h

4

M

71

71

Pancreas NET

Liver

7054

7134

4

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 192 h

5

F

63

56

Pancreas NET

Liver

7323

7071

4

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 72 h

6

M

59

79

Small intestine NET

Mesentery, liver

7207

7188

4

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 72 h, 192 h

7

F

82

57

Pancreas NET

Liver

7177

7239

4

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 72 h, 192 h

8

M

61

74

Small intestine NET

Nodes, mesentery, liver, bone

7298

7210

4

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 72 h, 192 h

9

M

70

88

Small intestine NET

Liver, bone

7222

7158

4

4 h, 24 h, 192 h

4 h, 24 h, 72 h, 192 h

10

M

78

89

Large intestine NET

Nodes, liver

7162

6620

2

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 192 h

11

M

53

70

Small intestine NET

Liver, bone

7102

7260

3

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 72 h, 192 h

12

M

74

70

Small intestine NET

Nodes, mesentery

7288

7578

3

4 h, 24 h, 72 h, 192 h

4 h, 24 h, 72 h, 192 h

  1. NA not available, C cycle, NET neuroendocrine tumor, † patient dead